StockpollyBeta
Get App
Popularity #1,842
KYTX · NASDAQ · Biotechnology

Kyverna Therapeutics (KYTX)

Develops miv-cel, an autologous CD19 CAR-T candidate for B-cell-driven autoimmune diseases.

$7.05
vs last close−0.46 (−6.19%)

In millions of USD, except per-share figures

In millionsQ3 FY23Sep 2023Q4 FY23Dec 2023Q1 FY24Mar 2024Q2 FY24Jun 2024Q3 FY24Sep 2024Q4 FY24Dec 2024Q1 FY25Mar 2025Q2 FY25Jun 2025Q3 FY25Sep 2025Q4 FY25Dec 2025Q1 FY26Mar 2026Q2 FY26Jun 2026
Cost of revenue01700291110000
Gross profit0−1700−29−1−1−10000
1640331040474439394140
Research & development14170272933373630303025
340688109891115
General & administrative340680109891115
Other expenses0−1700−270−1−10000
Operating income−16−210−33−39−41−47−44−39−39−41−40
110544322121
Interest income113544322222
Interest expense000000000011
Other non-operating income−1−10−5−2−4−3−2−2−2−2−2
Income before tax−15−210−29−34−37−45−42−37−38−40−38
Net income from continuing operations−15−210−29−34−37−45−42−37−38−40−38
Net income−15−210−29−34−37−45−42−37−38−40−38
EPS, basic−$0.36−$0.48−$1.12−$0.67−$0.80−$0.87−$1.03−$0.97−$0.85−$0.80−$0.66−$0.63
EPS, diluted−$0.36−$0.48−$1.12−$0.67−$0.80−$0.87−$1.03−$0.97−$0.85−$0.80−$0.66−$0.63
Weighted average shares, basic434324434343434343476061
Weighted average shares, diluted434324434343434343476061
EBITDA−15−200−28−37−37−44−42−36−37−39−37
Depreciation & amortization000101110000
EBIT−15−210−29−37−37−45−42−37−37−39−38